Amicus Therapeutics (FOLD) Stock Forecast & Price Target

$9.68 -0.41 (-4.06%)

(As of 11/15/2024 08:54 PM ET)

Amicus Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 9 Analyst Ratings

Sell
0

Hold
1

Buy
8

Based on 9 Wall Street analysts who have issued ratings for Amicus Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for FOLD.

Consensus Price Target

$17.63
82.08% Upside

According to the 9 analysts' twelve-month price targets for Amicus Therapeutics, the average price target is $17.63. The highest price target for FOLD is $21.00, while the lowest price target for FOLD is $15.00. The average price target represents a forecasted upside of 82.08% from the current price of $9.68.

FOLD Analyst Ratings Over Time

Type	Current Forecast 11/19/23 to 11/18/24	1 Month Ago 10/20/23 to 10/19/24	3 Months Ago 8/21/23 to 8/20/24	1 Year Ago 11/19/22 to 11/19/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	8 Buy rating(s)	8 Buy rating(s)	7 Buy rating(s)	4 Buy rating(s)
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$17.63	$17.13	$17.14	$16.17
Forecasted Upside	82.08% Upside	43.91% Upside	43.82% Upside	49.97% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Moderate Buy

The Harvard Business School proved his stock picking system works (Ad)

If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it.

Follow this link here we’ll add you to the guest list.

FOLD Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

FOLD Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Amicus Therapeutics Stock vs. The Competition

Type	Amicus Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.89	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	82.08% Upside	28,621.01% Upside	9.87% Upside
News Sentiment Rating	Positive News See Recent FOLD News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/12/2024	JPMorgan Chase & Co. 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$16.00 ➝ $17.00	+58.73%
11/7/2024	Guggenheim 3 of 5 stars	D. Chattopadhyay Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Buy ➝ Buy	$13.00 ➝ $15.00	+37.61%
11/7/2024	Cantor Fitzgerald 3 of 5 stars		Boost Target	Overweight ➝ Overweight	$20.00 ➝ $21.00	+92.84%
11/7/2024	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Hold
10/17/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$13.00 ➝ $15.00	+24.79%
10/11/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$19.00 ➝ $18.00	+75.10%
The Harvard Business School proved his stock picking system works (Ad) If you missed our last email, I hope you see this one. You see, this Tuesday afternoon we’re sitting down with the #1 ranked stock picker in North America. A man who’s beat out 16,000 stock market professionals on Sum Zero to claim the top spot… He was amongst the first to recommend many of today’s most dominant companies, including both Apple and Nvidia. And for the first time on a large scale, he’s going to share the stock rating system that made it all possible… Not only has this system been proven to generate significant alpha by The Harvard Business School… It also earned a patent from the US government… The technology behind this system is out of this world, and our #1 stock picker has agreed to let us test a number of stocks against it. Follow this link here we’ll add you to the guest list.
9/6/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$18.00	+53.98%
5/30/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Overweight	$18.00	+92.31%
5/10/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$20.00 ➝ $19.00	+105.85%
3/2/2023	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$10.00 ➝ $11.00	-18.82%
1/18/2023	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy	$14.00 ➝ $16.00	+28.82%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 02:32 AM ET.

FOLD Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Amicus Therapeutics is $17.63, with a high forecast of $21.00 and a low forecast of $15.00.
: 9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Amicus Therapeutics in the last year. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" FOLD shares.
: According to analysts, Amicus Therapeutics's stock has a predicted upside of 82.08% based on their 12-month stock forecasts.
: Amicus Therapeutics has been rated by research analysts at Bank of America, Cantor Fitzgerald, Guggenheim, Jefferies Financial Group, JPMorgan Chase & Co., Morgan Stanley, and Needham & Company LLC in the past 90 days.
: Analysts like Amicus Therapeutics more than other "medical" companies. The consensus rating score for Amicus Therapeutics is 2.89 while the average consensus rating score for "medical" companies is 2.80. Learn more on how FOLD compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

The Harvard Business School proved his stock picking system works (Ad)

Follow this link here we’ll add you to the guest list.

This page (NASDAQ:FOLD) was last updated on 11/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Amicus Therapeutics (FOLD) Stock Forecast & Price Target